BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

BiondVax Pharmaceuticals Price Performance

NASDAQ BVXV opened at $2.77 on Tuesday. The company has a quick ratio of 5.76, a current ratio of 5.76 and a debt-to-equity ratio of 5.92. BiondVax Pharmaceuticals has a 12-month low of $2.37 and a 12-month high of $22.90. The company has a market capitalization of $3.97 million, a PE ratio of -0.69 and a beta of 2.65. The firm’s 50 day moving average is $6.01 and its 200-day moving average is $8.55.

BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last posted its quarterly earnings data on Wednesday, November 30th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16. Equities research analysts anticipate that BiondVax Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of BiondVax Pharmaceuticals

An institutional investor recently raised its position in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. grew its holdings in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 163,423 shares of the company’s stock after purchasing an additional 113,418 shares during the period. Envestnet Asset Management Inc. owned about 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent quarter.

BiondVax Pharmaceuticals Company Profile

(Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.